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Background/Purpose: The role of proteinuria in disease severity of preeclampsia and gestational hyper-
tension has not been determined. The objective of this study was to compare the effects of disease severity
on maternal complications and pregnancy outcome between women with severe preeclampsia and women
with gestational hypertension.
Methods: A retrospective case-control study using daily records from the birth registry for the years 1994
to 2003 was conducted. Cases (n = 364) were defined as women with severe preeclampsia. Controls
(n = 249) were selected from women with gestational hypertension. The outcome measures were maternal
complications and perinatal-related factors.
Results: Women with severe preeclampsia had an increased risk of intrauterine growth restriction (ad-
justed odds ratio [aOR], 2.16; 95% confidence interval [CI], 1.10–4.24; p = 0.026). Risk factors associated
with severe preeclampsia patients were lack of prenatal care (aOR, 2.95; 95% CI, 1.45–5.99), systolic
blood pressure ≥ 180 mmHg (aOR, 14.3; 95% CI, 1.69–121.0), and diastolic blood pressure ≥ 105 mmHg
(aOR, 21.2; 95% CI, 6.99–64.3) compared with women with gestational hypertension in Model I. When
we added proteinuria as a variable, two significant risk factors, diastolic blood pressure ≥ 105 mmHg
(aOR, 18.2; 95% CI, 4.85–68.3) and significant proteinuria (aOR, 1.01; 95% CI, 1.006–1.014), were asso-
ciated with severe preeclampsia patients in Model II. A subgroup of women with gestational hypertension
and proteinuria had an increased risk of placental abruption (unadjusted OR, 4.36; 95% CI, 1.05–18.1)
and disseminated intravascular coagulation (unadjusted OR, 6.46; 95% CI, 1.05–39.8). Finally, maternal
complications (aOR, 2.59; 95% CI, 1.34–5.04) became the single significant factor associated with gesta-
tional hypertension and proteinuria.
Conclusion: Proteinuria may play a role in the progression of gestational hypertension to severe forms of
preeclampsia associated with subsequent maternal complications and extremely-low-birth-weight babies.
[J Formos Med Assoc 2008;107(2):129–138]
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ORIGINAL ARTICLE
Preeclampsia is a disease of multiple organ sys-
tems that is unique to pregnancy and is often as-
sociated with significant maternal and neonatal
morbidity and mortality, especially when it is se-
vere and occurs well before term.1–4 Because the
only cure for severe preeclampsia is delivery, there
is universal consensus to deliver patients if the
disease develops after 34 weeks of gestation or if
there is evidence of maternal complications and
fetal distress before that time.3 Despite the severity
of disease of both preeclampsia and gestational
hypertension, differences in risk factors between
severe preeclampsia and gestational hypertension
may increase controversies over expectant versus
aggressive treatment, and there is insufficient lit-
erature on Asian women with preeclampsia and
gestational hypertension regarding the issue of
maternal complications. As there is a discrepancy
between the definition of mild to moderate pre-
eclampsia and gestational hypertension in terms
of proteinuria, the less than 300 mg/24 hours of
slight proteinuria may not belong to the pre-
eclampsia group. We might raise a question, “Is
gestational hypertension an early sign of pre-
eclampsia?”5 We then tested the hypothesis that
the presence of significant proteinuria may have
an impact on pregnancy outcome. In addition, the
subgroup of gestational hypertension with slight
proteinuria (< 150 mg/24 hours) might have more
adverse perinatal outcome than the subgroup
without proteinuria. The main purpose of this
study was to identify differences in the effect of hy-
pertension and its management between two enti-
ties of hypertension—severe preeclampsia and
gestational hypertension—with regard to maternal
complications and perinatal outcome in Taiwanese
women with hypertensive disorders. Another pur-
pose was to investigate whether the presence of
proteinuria in women with gestational hyperten-
sion may have an impact on pregnancy outcome.
Methods
This study was a retrospective cohort analysis of
pregnant women with preeclampsia from January
1994 through 2003 at a single tertiary care and
academic center. Data were obtained from daily
records of a birth registry and medical chart re-
view. A database containing clinical information
on pregnant women who received outpatient
services and inpatient services for delivery was
created. We used the American College of
Obstetricians and Gynecologists (ACOG) criteria
for the definitions of gestational hypertension
and severe preeclampsia.6–8
Severe preeclampsia was defined as the pres-
ence of one or more of the following criteria: (a)
blood pressure (BP) of 160 mmHg or higher sys-
tolic or 110 mmHg or higher diastolic on two oc-
casions at least 6 hours apart while the patient is
on bed rest; (b) proteinuria of 5 g or higher in a
24-hour urine specimen or 3 + or greater on two
random urine samples collected at least 4 hours
apart; (c) oliguria of less than 500 mL in 24 hours;
(d) cerebral or visual disturbances; (e) pulmonary
edema or cyanosis; (f) epigastric or right upper-
quadrant pain; (g) impaired liver function; (h)
thrombocytopenia; and (i) fetal growth restriction.
Eclampsia was defined as seizures occurring in a
woman with preeclampsia that cannot be attrib-
uted to another cause but may complicate severe
preeclampsia.
The definition of gestational hypertension was
a systolic BP of at least 140 mmHg and/or a dias-
tolic BP of at least 90 mmHg on at least two occa-
sions at least 6 hours apart after the 20th week of
gestation in women known to be normotensive
before pregnancy and before 20 weeks of gesta-
tion. The BP recordings used to establish the di-
agnosis should be made no more than 7 days
apart. Women with gestational hypertension and
less than 1+ to 2+ proteinuria were included in
our study cohort. Proteinuria was defined as 
the urinary excretion of ≥ 0.3 g of protein in a 24-
hour specimen. This will usually correlate with
≥ 30 mg/dL (≥ 1 + reading on dipstick).7 Significant
proteinuria is demonstrated when there is more
than 500 mg of protein as above.
Women who met the above criteria included
women with severe preeclampsia (case) (n = 364)
and women with gestational hypertension 
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(control) (n = 249) who did or did not have their
prenatal care at the study hospital but did deliver
their babies at the study hospital. The exclusion
criteria for this study were missing or unavailable
data from clinical visit or delivery and no avail-
able record in our obstetric daily logbook. Based
on our criteria, we excluded patients with chronic
hypertension (n = 39) and patients with chronic
hypertension superimposed preeclampsia (n = 7).
Although the complex features of the disease en-
tity accurately reflected the disease patterns in a
tertiary center, we believe that it may not be nec-
essary to exclude all women with the following
preexisting or concurrent medical diseases during
their pregnancies. These patients encompassed a
wide range of preexisting or concurrent diseases
including: uterine myoma (n = 7); gestational di-
abetes mellitus, insulin-dependent diabetes mel-
litus and glucose intolerance (n = 6); nephropathy,
uremia, acute renal failure, and glomerulonephritis
(n = 9); hepatitis (n = 1); recurrent pituitary tumor
(n = 1); tuberculosis and pleural effusion (n = 1);
hyperthyroidism and thyroiditis (n = 4); hypo-
parathyroidism (n = 1); adrenal cortical adenoma
(n = 1); thrombotic thrombocytopenic purpura
(n=1); immune thrombocytopenic purpura (n=1);
angina and coronary heart disease (n = 2); cerebral
infarction and intracerebral hemorrhage (n = 2);
L3-4 dislocation (n = 1); systemic lupus erythe-
matosus (n=3); mastitis (n=1); urinary tract in-
fection; and acute pyelonephritis (n = 2). Some
patients may have had more than one of the
listed preexisting medical diseases during their
pregnancies.
All patients were admitted to the labor and
delivery area and carefully evaluated. They were
counseled about maternal and perinatal risks with
regard to severe preeclampsia. Initial drug therapy
consisted primarily of intravenous magnesium
sulfate to prevent convulsions and bolus injections
of hydralazine or labetalol to maintain diastolic
blood pressure (DBP) below 100 mmHg. Intra-
venous fluids and urinary output were carefully
monitored during the observation period. Oral
antihypertensive medications were then given to
maintain the diastolic pressure between 90 and
100 mmHg. The antihypertensive drugs used ini-
tially were methyldopa, hydralazine and labetalol;
nifedipine was used after patients delivered their
babies. Corticosteroids were used routinely to ac-
celerate fetal lung maturity in all cases when the
gestational age was more than 25 weeks. Absent
fetal movement was evaluated by a non-stress test
and biophysical profile and was then managed
according to the findings of the tests.
Patients with HELLP (hemolysis, elevated
liver enzymes, low platelets) syndrome were also
recruited for this investigation. Before 34 weeks
of gestation, patients received 12.5 mg of dexa-
methasone intramuscularly over 12 hours in three
doses for a total of 37.5 mg. The exclusion crite-
rion was clinical evidence of chorioamnionitis at
delivery. In our unit, magnesium sulfate was
started in women as a prophylactic measure when
there was concern about seizure. We did not rou-
tinely use high-dose dexamethasone or cortico-
steroids for rescue therapy for maternal HELLP.
However, whether or not to use antepartum cor-
ticosteroids for fetal indications of lung maturity
was often decided by the physician in-charge. We
defined aggressive management based on criteria
used for immediate delivery within 48 hours 
including a non-reassuring fetal heart rate tracing,
evidence of HELLP syndrome, eclampsia, preterm
labor, preterm rupture of membranes, and un-
controlled hypertension. Expectant management
included assessment of the woman’s condition,
bed rest, antihypertensive agents, chronic par-
enteral magnesium sulfate, plasma volume ex-
panders (crystalloids, albumin, fresh frozen
plasma), and steroids (dexamethasone or be-
tamethasone). The decision of whether to use ag-
gressive or expectant management was made
based on physician preference.
The study was approved by the institutional
review board of Chang Gung Memorial Hospital,
Taoyuan, Taiwan (No. 96-1094B).
Statistical analysis
Statistical comparison of clinical and demographic
factors between patients with severe preeclampsia
and patients with gestational hypertension who
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delivered babies was carried out using Pearson’s
χ2 test and Student’s t test. Univariate analysis
was carried out and multiple logistic regression
analysis was performed to control for potential
confounding variables. Statistical procedures
were performed with SPSS version 11.0 (SPSS
Inc., Chicago, IL, USA). Data are presented as
means ± standard deviation. A p value of less than
0.05 was considered statistically significant.
Results
There were a total of 55,763 deliveries during the
study period. The 661 patients who met the in-
clusion criteria during pregnancy and who were
treated at Chang Gung Memorial Hospital were
recruited and included in the analysis. In our study
cohort, 199 (32.5%) patients were noted to have
maternal complications. Of the 661 women with
preeclampsia and gestational hypertension, 48
had mild to moderate preeclampsia and 364 had
severe preeclampsia, including 34 with HELLP
syndrome and 34 with eclampsia. There were
249 patients who had gestational hypertension.
The mean age of the patients was 30.6 ± 5.3 years
(range, 13–48 years). There were 210 (34.3%)
patients who were nulliparous. The majority of
patients, 398 (60.7%), were non-referral patients.
There were 38 (6.2%) women with multiple
pregnancies. With regard to HELLP cases, the cor-
relation between cesarean delivery and the two
treatment strategies (aggressive and expectant)
was not significant (r = 0.09, p = 0.53). However,
the correlation between maternal multiple organ
dysfunction syndrome and the two modes of in-
tervention was significant (r = 0.349, p = 0.012).
Various maternal characteristics are summa-
rized in Table 1. There were no significant differ-
ences in the clinical manifestations of disease with
respect to maternal age, the diagnosis of hyper-
tension with regard to gestational age, gravida, or
multiple pregnancies.
Table 2 shows factors associated with the devel-
opment of severe preeclampsia. The maternal fac-
tors that were significantly associated with severe
preeclampsia included: age ≥ 40 years; presence
of proteinuria; referral (no prenatal care) versus
non-referral (prenatal care) status; and whether
or not there were associated medical diseases such
as HELLP syndrome. As for neonatal outcomes,
the rate of cesarean delivery was significantly
higher in the group with severe preeclampsia
(87.3%); this mode of delivery was usually for
fetal indications.9 Furthermore, relative growth re-
striction revealed that a greater proportion of
women with severe preeclampsia had preterm
deliveries (78%), low-birth-weight (LBW) babies
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Table 1. Characteristics of the study population
Severe preeclampsia Gestational hypertension
p*
(n = 364) (n = 249)
Maternal age (yr) 30.9 ± 5.4 30.1 ± 5.4 0.049
Systolic BP (mmHg) 179.5 ± 19.7 147.9 ± 8.1 < 0.001
Diastolic BP (mmHg) 108.7 ± 16.5 87.8 ± 10.2 < 0.001
Gravida 2.6 ± 1.7 2.4 ± 1.7 0.219
Parity 1.8 ± 1.1 1.6 ± 1.0 0.023
Multiple pregnancies (%) 22 (6.0) 16 (6.4) 0.866
Gestational age at diagnosis (wk) 29.3 ± 7.9 29.2 ± 8.2 0.813
Gestational age at delivery (wk) 33.7 ± 4.0 35.7 ± 3.4 < 0.001
Cesarean delivery (%) 315 (87.3) 192 (77.4) 0.001
Mean birth weight (g) 1957.0 ± 896.1 2459.7 ± 794.6 < 0.001
Preterm labor (%) 278 (77.7) 128 (52.2) < 0.001
Maternal complications (%) 137 (37.6) 62 (24.9) 0.001
*Student’s t test and χ2 analysis. BP = blood pressure.
(74.3%), very-low-birth-weight (VLBW) babies
(33.6%), and extremely low-birth-weight (ELBW)
babies (17.2%) compared to the control group.
Table 3 presents the results of univariate
analysis with regard to maternal complications
and pregnancy outcome in patients with severe
preeclampsia. The significant factors regarding
maternal complications that were present in the
severe preeclampsia group included HELLP, hyper-
tensive retinopathy, referral status and associated
concurrent medical complications or complex
diseases. Patients with severe preeclampsia were
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Table 2. Factors associated with the development of severe preeclampsia
Severe preeclampsia Gestational hypertension p
(n = 364) (n = 249)
Maternal age ≥ 34 yr (n/N) 103 (28.3) 57 (22.9) 0.160
Nulliparity (n/N) 118 (32.5) 92 (37.1) 0.260
Parity ≥ 3 (n/N) 80/361 (22.2) 52/296 (17.6) 0.171
Gestational age at diagnosis (wk)
≤ 24 (n/N) 72/361 (19.9) 60/245 (24.5) 0.193
25–28 (n/N) 40/361 (11.1) 25/245 (10.2) 0.790
29–32 (n/N) 93/361 (25.8) 52/245 (21.2) 0.209
33–36 (n/N) 114/361 (31.6) 70/246 (28.5) 0.420
≥ 37 (n/N) 41/360 (11.4) 39/245 (15.9) 0.113
SBP ≥ 180 mmHg (n/N) 149 (40.9) 1 (0.40) < 0.001
DBP ≥ 105 mmHg (n/N) 210 (58.0) 10 (4.02) < 0.001
Factors related to maternal complications
Age ≥ 40 yr (n/N) 33 (9.1) 10 (4.02) 0.016
34 ≤ age < 40 yr (n/N) 78 (21.4) 47 (18.9) 0.476
Age < 34 yr (n/N) 253 (69.5) 192 (77.1) 0.043
Proteinuria (n/N) 118/196 (60.2)* 0/86 (0) < 0.001
HELLP syndrome (n/N) 34 (9.34) 11 (4.42) 0.026
Eclampsia (n/N) 34 (9.37) 14 (5.62) 0.095
Abruptio placentae (n/N) 18 (4.96) 8 (3.21) 0.317
Referral vs. non-referral† (n/N) 156/232 (67.2) 28/107 (26.2) < 0.001
Associated medical diseases (n/N) 137 (37.6) 62 (24.9) 0.001
Maternal mortality (n/N) 3 (0.82) 2 (0.80) 1.00
Fetal conditions and pregnancy outcome
Delivery at < 37 wk (n/N) 278 (77.7) 128 (52.2) < 0.001
Delivery at < 27 wk (n/N) 18/353 (5.10) 5/244 (2.05) 0.082
27 wk ≤ delivery < 30 wk (n/N) 34/353 (9.63) 6/244 (2.46) 0.001
Delivery at ≥ 30 wk (n/N) 301/353 (85.3) 233/244 (95.5) < 0.001
Birth weight < 2500 g (n/N) 266/358 (74.3) 111/244 (45.5) < 0.001
Birth weight < 1500 g (n/N) 121/360 (33.6) 34/245 (13.9) < 0.001
Birth weight < 1000 g (n/N) 62/360 (17.2) 12/245 (4.90) < 0.001
Neonatal death (n/N) 32/363 (8.82) 9/247 (3.64) 0.013
*Significant proteinuria ≥ 500 mg/24 hours; †no prenatal care vs. care. SBP = systolic blood pressure; DBP = diastolic blood pressure;
HELLP = hemolysis, elevated liver enzymes, low platelets.
more likely to have preterm labor and preterm
delivery between 27 and 30 weeks of gestation
(odds ratio [OR], 4.23; 95% confidence interval
[CI], 1.75–10.2; p = 0.001), LBW babies, VLBW
babies, ELBW babies, intrauterine fetal demise
(IUFD), and poor Apgar score. The associated
significant factors with the highest ORs (which
included maternal medical complications, preterm
labor, and prenatal care status, together with LBW,
VLBW and ELBW babies) were also found to be
relatively cumulative.
Table 4 shows the results of multiple logistic
regression analyses in the absence of proteinuria
as a variable as in Model I. Because significant pro-
teinuria may play a major role in these two entities
in terms of disease severity, the associated factors
without considering the proteinuria variable that
were identified to be significantly correlated with
increased risk of severe preeclampsia included
patients not receiving prenatal care versus receiv-
ing prenatal care (adjusted OR, 2.95; 95% CI,
1.45–5.99; p = 0.003), systolic blood pressure
(SBP) ≥ 180 mmHg (adjusted OR, 14.3; 95% CI,
1.69–121.0; p= 0.015), DBP ≥ 105mmHg (adjusted
OR, 21.2; 95% CI, 6.99–64.3; p< 0.001), and in-
trauterine growth restriction (IUGR) (adjusted
OR, 2.16; 95% CI, 1.09–4.24; p = 0.026). With
respect to HELLP, women with severe preeclampsia
seemed to have a marginally protective effect (ad-
justed OR, 0.327; 95% CI, 0.10–1.08; p = 0.066).
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Table 3. Univariate analysis of factors associated with severe preeclampsia
OR 95% CI p
Maternal complications
DIC 1.38 0.47–4.08 0.562
Sepsis 1.56 0.47–5.11 0.466
Eclampsia 1.73 0.91–3.30 0.094
HELLP 2.23 1.11–4.49 0.025
Abruptio placentae 1.57 0.67–3.67 0.297
Pulmonary edema 2.38 0.87–6.53 0.092
Acute renal failure 1.23 0.53–2.82 0.632
Intracerebral hemorrhage 4.83 0.59–39.5 0.142
Hypertensive retinopathy 2.99 1.21–7.39 0.018
Associated medical complications 1.82 1.27–2.60 0.001
Proteinuria 1.01 1.007–1.014 0.001
Prenatal non-care vs. care 5.79 3.47–9.65 < 0.001
Maternal mortality 1.03 0.17–6.19 0.977
Pregnancy outcome
Preterm labor 3.18 2.23–4.52 < 0.001
LBW (< 2500 g) 3.46 2.45–4.90 < 0.001
VLBW (< 1500 g) 3.14 2.06–4.80 < 0.001
ELBW (< 1000 g) 4.04 2.13–7.67 < 0.001
1-min Apgar score < 5 2.95 1.82–4.79 < 0.001
5-min Apgar score < 7 2.96 1.71–5.11 < 0.001
IUGR 1.53 1.50–10.4 0.005
Date of delivery < 27 wk 3.94 0.21–14.1 0.615
27 wk < date of delivery < 30 wk 4.23 1.75–10.2 0.001
Date of delivery > 30 wk 0.27 0.14–0.54 < 0.001
IUFD and neonatal death 2.56 1.20–5.46 0.015
OR = odds ratio; CI = confidence interval; DIC = disseminated intravascular coagulation; HELLP = hemolysis, elevated liver enzymes,
low platelets; LBW = low birth weight; VLBW = very low birth weight; ELBW = extremely low birth weight; IUGR = intrauterine growth
restriction; IUFD = intrauterine fetal demise.
Table 5 presents the risk factors associated
with severe preeclampsia after considering the
presence of significant proteinuria as in Model II.
DBP ≥ 105 mmHg became a significant risk factor
(adjusted OR, 18.21; 95% CI, 4.85–68.3; p < 0.001)
for patients with severe preeclampsia.
Table 6 shows that the presence of protein-
uria, even when not significant (< 1+ to 2 +,
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Table 4. Multiple logistic regression analysis between patients with severe preeclampsia and gestational
hypertension for significant associated factors during pregnancy (Model 1)*
Study factors Adjusted OR 95% CI p
No prenatal care vs. care 2.95 1.45–5.99 0.003
SBP ≥ 180 mmHg 14.3 1.69–121.0 0.015
DBP ≥ 105 mmHg 21.2 6.99–64.3 < 0.001
HELLP syndrome 0.327 0.10–1.08 0.066
ELBW 2.86 0.91–8.99 0.072
IUGR 2.16 1.10–4.24 0.026
*Model I: without considering the proteinuria variable. OR = odds ratio; CI = confidence interval; SBP = systolic blood pressure; DBP =
diastolic blood pressure; HELLP = hemolysis, elevated liver enzymes, low platelets; ELBW = extremely low birth weight; IUGR =
intrauterine growth restriction.
Table 5. Multiple logistic regression analysis between patients with severe preeclampsia and gestational
hypertension for significant associated factors during pregnancy (Model II)*
Study factors Adjusted OR 95% CI p
Significant proteinuria 1.01 1.006–1.014 < 0.001
DBP ≥ 105 mmHg 18.21 4.85–68.29 < 0.001
*Model II: with the addition of the proteinuria variable. OR = odds ratio; CI = confidence interval; DBP = diastolic blood pressure.
Table 6. Maternal complications and pregnancy outcome in women with gestational hypertension for
significant factors associated with proteinuria
Unadjusted OR 95% CI p Adjusted OR (95% CI) p
Maternal complications 2.59 1.34–5.04 0.005* 2.59 (1.34–5.04) 0.005*
Eclampsia 0.67 0.14–3.08 0.60
DIC 6.46 1.05–39.8 0.04*
HELLP 1.57 0.40–6.13 0.52
MODS 1.88 0.55–6.37 0.31
Placental abruption 4.36 1.05–18.1 0.04*
Pulmonary edema 2.79 0.45–17.2 0.27
Pregnancy outcome
Preterm labor 0.94 0.50–1.76 0.85
LBW (< 2500 g) 0.82 0.43–1.54 0.53
VLBW (< 1500 g) 0.83 0.33–2.14 0.70
ELBW (< 1000 g) 2.16 0.62–7.49 0.23
IUGR 0.64 0.32–1.29 0.21
IUFD 1.19 0.24–5.93 0.83
1-min Apgar score < 5 1.43 0.53–3.82 0.48
5-min Apgar score < 7 0.81 0.23–2.93 0.75
*Statistical significance. OR = odds ratio; CI = confidence interval; DIC = disseminated intravascular coagulation; HELLP = hemolysis,
elevated liver enzymes, low platelets; MODS = multiple organ dysfunction syndrome; LBW = low birth weight; VLBW = very low birth
weight; ELBW = extremely low birth weight; IUGR = intrauterine growth restriction; IUFD = intrauterine fetal demise.
< 100 mg/dL), in women with gestational hyper-
tension may increase the risk of maternal com-
plications such as disseminated intravascular
coagulation (unadjusted OR, 6.46; 95% CI,
1.05–39.8; p = 0.04) and placental abruption (un-
adjusted OR, 4.36; 95% CI, 1.05–18.1; p = 0.04)
by four- to six-fold, as well as maternal complica-
tions (adjusted OR, 2.23; 95% CI, 1.29–3.88;
p = 0.04). After multiple logistic regression analy-
sis, the risk of maternal complications was al-
most three-fold greater (adjusted OR, 2.59; 95%
CI, 1.34–5.04; p = 0.005) than in women with
gestational hypertension without proteinuria.
Discussion
There are three main findings from our study that
are related to women with severe preeclampsia.
First, patients with severe preeclampsia were
more likely to be found in the referral (no prena-
tal care) group; similarly, those patients often
had another medical disease or pregnancy com-
plications. Second, in terms of neonatal out-
comes, LBW, VLBW and ELBW babies were found
more often in the severe preeclampsia group,
which may be a result of the fetal indications that
were refractory to control of maternal hyperten-
sion. This finding was consistent with the occur-
rence of preterm delivery. The relative strength of
risk compatible with dose-response is shown as a
3.46-fold, 3.14-fold and 4.04-fold increased risk
of preterm delivery with LBW, VLBW and ELBW
babies. There was also a 2.56-fold increased risk of
IUFD in the severe preeclampsia group. Finally,
we should not neglect any slight proteinuria that
occurs early on or is noted after their prenatal
care visits. Slight proteinuria could be an early
sign in gestational hypertension patients because
they may progress to preeclampsia and be associ-
ated with maternal and medical complications.
Maternal complications
The optimal management of pregnancies com-
plicated by severe preeclampsia remains a con-
troversial issue in obstetrics. One important issue
concerns the decision of whether to initiate ex-
pectant management or immediate delivery.10
Expectant management allows for prolongation of
pregnancy which potentially can improve neona-
tal outcome. However, expectant management
poses a significant risk with regard to maternal
complications and neonatal adverse outcome.
Our results emphasize that in referral patients
who received no prenatal care, SBP > 180 mmHg
and DBP > 105 mmHg and preterm delivery be-
tween 27 and 30 weeks of gestation are the key
features of women with severe preeclampsia and
they are more likely to have LBW and IUGR babies.
Maternal complications generally correlated
with the severity of preeclampsia, and we also
demonstrated with a relatively high OR that no
prenatal care and an Apgar score < 5 at 1 minute
were associated with poor fetal outcome.11 These
results suggest multiorgan involvement in severe
preeclampsia.12 Maternal complications are those
related to the effect of severe preeclampsia on
multiple organ systems, together with those associ-
ated with medical complications during pregnancy
and the course of labor.13 Pregnant women of ad-
vanced age of more than 40 years could be a new
population in Taiwan, and our findings provide
evidence for a high-risk pregnancy of severe pre-
eclampsia in this group. These findings were dif-
ferent from those of Eskenazi et al’s study14 but
consistent with Knuist et al’s results that ad-
vanced maternal age was a significant predictor of
preeclampsia.15 The increased risk of hyperten-
sive retinopathy in univariate analysis may sug-
gest that routine ophthalmology consultation
should be recommended for women with severe
preeclampsia. However, they do not appear after
multiple regression model calculations.
There are many factors that contribute to 
the prognosis of gestational hypertension. A well-
established BP control protocol may prolong the
pregnancy, and gestational hypertension without
proteinuria may indicate relatively fair prognosis.
However, one should pay heed to severe gesta-
tional hypertension patients, especially when they
have slight proteinuria at prenatal visits during
their pregnancy. In addition, some obstetric events
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unrelated to BP may predispose to immediate
delivery. Nonetheless, the ultimate treatment
goal in severe preeclampsia is delivery, which
seems like a final resolution with regard to BP
control that is refractory to pharmacologic ther-
apy and other factors such as placental abruption
and acute or chronic fetal distress. Furthermore,
because of the features of a retrospective study, an
outcome-oriented risk-assessment approach
should be discussed and emphasized.
Pregnancy outcome
Gestational age is the variable that is the strongest
predictor of fetal mortality and morbidity, espe-
cially at less than 30 weeks of gestation.16 In uni-
variate analysis, delivery between 27 and 30
weeks of gestation was a significant risk factor for
women with severe preeclampsia (OR, 4.23;
95% CI, 1.75–10.2; p = 0.001). However, in mul-
tivariate analysis, this variable disappeared.
Comparison with the result of IUFD revealed
that women with severe preeclampsia had an in-
creased risk (OR, 2.56; 95% CI, 1.20–5.46;
p = 0.015). This may be consistent with a previ-
ous study which showed that neonatal morbid-
ity and mortality were related to gestational age
of onset with expectant management.17 In addi-
tion, the presence of IUGR appears to be detri-
mental rather than protective for neonatal
survival and severe preeclampsia and limits ex-
pectant management. Our series indicated that
women with severe preeclampsia may have a sta-
tistically increased risk of IUGR (OR, 2.16; 95%
CI, 1.10–4.24; p = 0.026), which is consistent
with Witlin et al’s findings which suggested that
IUGR was associated with decreased survival in
univariate analysis (OR, 5.88; 95% CI, 1.81–19.26;
p = 0.001).18 Interestingly, our results revealed
that the marginally protective effect of HELLP
was also implicated that to those of such disease
may not only demonstrate in severe preeclampsia
patients alone. For fear of the maternal compli-
cations in severe preeclampsia patients, precau-
tionary strategies, well-prepared protocol and
timely diagnosis could prevent the impending
adverse events in suspected HELLP patients. The
relatively high OR in terms of the risk of IUGR
babies in the severe preeclampsia group was
comparable to that of Chammas et al19 who re-
ported that immediate delivery may be beneficial
for LBW and IUGR babies of severe preeclampsia
patients.
The problems associated with delivery between
27 and 30 weeks of gestation could be attributa-
ble to refractory hypertension control in women
with severe preeclampsia. Not only was there a
high cesarean section rate but it was also noted
that there was a prospect of neurodevelopmental
disability in these extremely preterm newborns
which really presents a clinical challenge.20
The strengths of our study were that it focused
on Asian women (Taiwanese and Chinese); used
clinical data from daily practice; was aware of the
validity and reliability of data recording, coding,
and keying in data accurately; delineated a whole
spectrum of disease severity for preeclampsia; dealt
with the effect of slight or little proteinuria in a
subgroup of gestational hypertension patients and
their progression later on and added some policy
issue concerns regarding prenatal care versus no
prenatal care,21 which has a significant impact on
public health affecting both mothers and their in-
fants alike whether they are Taiwanese or Chinese.
Our study still had some limitations: it was
hospital-based and unicenter-oriented; having a
retrospective design, it did not have complete so-
cioeconomic data or enough family history; the
sample size was small; it did not entirely exclude
preexisting medical conditions; some “key” lab
data that could be used to diagnose some specific
diseases were lacking; a model was not proposed
in advance; clinical data were not used to monitor
the progression from gestational hypertension to
preeclampsia; it may not be easy to distinguish
whether lack of BP control or disease per se alone
affected pregnancy outcome; there was no stan-
dardized physicians’ practice style or set well-
established research protocol; and it was only
performed from the perspective of hospital-
oriented health care and medical center-based,
and did not integrate or incorporate community
health care services as a health care system model.
Factors associated with preeclampsia and gestational hypertension
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We suggested that women with severe pre-
eclampsia have a greater chance to develop ma-
ternal complications and have a poor neonatal
outcome, especially if they had not received pre-
natal care. The risk factor in women with gesta-
tional hypertension associated with maternal
complications and poor pregnancy outcome was
slight proteinuria that may lead to a greater like-
lihood of DIC and placental abruption. Risk factors
associated with severe preeclampsia were prenatal
care status, advanced maternal age, SBP and DBP,
and significant proteinuria. In addition, with re-
gard to the effect of gestational hypertension in
patients with mild proteinuria, maternal compli-
cations became the only significant factor that
contributed to pregnancy outcome. Although sig-
nificant proteinuria was the main diagnostic 
criteria of severe preeclampsia, the importance of
severe gestational hypertension without protein-
uria or mild gestational hypertension with slight
proteinuria cannot be overemphasized. We believe
that these associated factors should be described
to appropriately counseled patients. In our view, the
important benefits of successful consultation and
prenatal care may outweigh the risks encountered
in women with hypertensive disorders in further
describing to these patients the risks and possible
outcomes before their pregnancy and delivery.
In conclusion, severe preeclampsia in women
was significantly associated with maternal com-
plications and preterm delivery, as well as LBW
babies. Proteinuria may play some role in the
progression of gestational hypertension to severe
forms of preeclampsia associated with subse-
quent maternal complications and ELBW babies.
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